Which peptides are studied in relation to lean mass preservation?
A research-supply overview of peptides investigated in relation to lean mass preservation, including trevogrumab, garetosmab, and GLP-1 receptor agonist combinations, with study models and identifiers.
Peptides studied in relation to lean mass preservation include trevogrumab (an anti-myostatin antibody) and garetosmab (an anti-activin A antibody), both investigated in combination with semaglutide in clinical trials [2]. These compounds are not peptides in the classical sense but are protein-based biologics; however, they are frequently grouped with peptide research due to their amino acid composition and injectable route. The formal identifiers for these compounds are not provided in the evidence block; however, their study in obesity-related lean mass preservation is documented [2].
The pathway or receptor family central to this research involves the myostatin/activin signaling axis, which regulates muscle growth and differentiation [2].
Research Studies
Trevogrumab and myostatin inhibition in obesity models
Trevogrumab is an experimental drug studied in combination with semaglutide for weight loss, fat loss, and lean mass preservation in adult patients with obesity [2]. The study is conducted in three parts: Part A in healthy participants, and Parts B and C in participants with obesity [2]. The aim includes assessing safety and efficacy when combined with semaglutide (Wegovy®) [2].
Garetosmab and activin A inhibition in combination with semaglutide
Garetosmab is another experimental drug tested with semaglutide in the same clinical trial [2]. The study evaluates trevogrumab or trevogrumab with garetosmab when taken with semaglutide, focusing on safety and how well they work in adult patients with obesity for weight loss, fat loss, and lean mass preservation [2].
Semaglutide and GLP-1 receptor agonist limitations in lean mass
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity treatment, achieving weight loss previously considered attainable only with bariatric surgery [1]. However, GLP-1-based therapies have revealed important limitations, including weight loss plateaus, substantial inter-individual variability, and weight regain upon discontinuation, underscoring the need for next-generation approaches [1]. This context highlights the rationale for studying peptides like trevogrumab and garetosmab to preserve lean mass during weight loss [2].
Multi-receptor agonists and next-generation metabolic modulators
Emerging multi-receptor agonists and next-generation metabolic modulators are being explored to address limitations of existing GLP-1RAs [1]. While specific peptides are not named in the evidence, the review discusses perspectives and controversies in obesity pharmacotherapy, including the need for approaches that may impact lean mass [1].
Animal and in vitro models for lean mass preservation
The evidence block does not provide specific animal or in vitro studies on lean mass preservation peptides. The clinical trial [2] is in human participants, and the review [1] discusses clinical therapies. No animal-only or in vitro data are cited in the evidence.
Comparative studies of peptides in lean mass preservation
No direct comparative studies between different peptides for lean mass preservation are described in the evidence. The clinical trial [2] compares trevogrumab alone and trevogrumab with garetosmab, both in combination with semaglutide, but the results are not yet reported in the evidence block.
Identifiers and sequences of studied peptides
The evidence block does not provide sequence, formula, or molecular weight for trevogrumab or garetosmab. Only their names and study context are available [2].
Table: Peptides and study models
| Peptide | Study Model | Combination | Reference |
|---|---|---|---|
| Trevogrumab | Human (healthy and obesity) | Semaglutide | [2] |
| Garetosmab | Human (obesity) | Semaglutide and trevogrumab | [2] |
| Semaglutide | Human (obesity) | Alone or with study drugs | [1], [2] |
If you are reading this for personal health reasons
This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
- [2] A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation